

-
Rafael PATERNOSTRO
Paternostro R; Becker J; Hofer BS; Panagl V; Schiffke H; Simbrunner B; Semmler G; Schwabl P; Scheiner B; Bucsics T; Bauer D; Binter T; Trauner M; Mandorfer M; Reiberger T, 2021. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.  Dig Liver Dis.
Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T, 2021. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.  Dig Liver Dis 53(3):345-352
Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Schwabl P; Stättermayer AF; Pinter M; Eigenbauer E; Quehenberger P; Trauner M; Reiberger T; Mandorfer M, 2021. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death.  Clin Gastroenterol Hepatol.
Paternostro R; Sieghart W; Trauner M; Pinter M, 2021. Cancer and hepatic steatosis.  ESMO Open 6(4):100185
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M, 2021. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.  Hepatol Int 15(4):922-933
Balcar L; Semmler G; Pomej K; Simbrunner B; Bauer D; Hartl L; Jachs M; Paternostro R; Bucsics T; Pinter M; Trauner M; Mandorfer M; Reiberger T; Scheiner B, 2021. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure.  United European Gastroenterol J 9(4):427-437
Hartl L; Jachs M; Desbalmes C; Schaufler D; Simbrunner B; Paternostro R; Schwabl P; Bauer DJM; Semmler G; Scheiner B; Bucsics T; Eigenbauer E; Marculescu R; Szekeres T; Peck-Radosavljevic M; Kastl S; Trauner M; Mandorfer M; Reiberger T, 2021. The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes.  Hepatol Int 15(5):1160-1173
Paternostro R; Bardach C; Hofer BS; Scheiner B; Schwabl P; Asenbaum U; Ba-Ssalamah A; Scharitzer M; Bucscis T; Simbrunner B; Bauer D; Trauner M; Mandorfer M; Reiberger T; Lampichler K, 2021. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension.  Liver Int 41(4):799-809
Bassegoda O; Olivas P; Turco L; Mandorfer M; Serra-Burriel M; Tellez L; Kwanten W; Laroyenne A; Farcau O; Alvarado E; Moga L; Vuille-Lessard E; Fortea JI; Ibañez L; Tosetti G; Vanwolleghem T; Larrue H; Burgos-Santamaría D; Stefanescu H; Paternostro R; Cippitelli A; Lens S; Augustin S; Llop E; Laleman W; Trebicka J; Chang J; Masnou H; Zipprich A; Miceli F; Semmler G; Forns X; Primignani M; Bañares R; Puente A; Berzigotti A; Rautou PE; Villanueva C; Ginès P; Garcia-Pagan JC; Procopet B; Bureau C; Albillos A; Francque S; Reiberger T; Schepis F; Graupera I; Hernandez-Gea V, 2021. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease.  Clin Gastroenterol Hepatol.
Jachs M; Hartl L; Schaufler D; Desbalmes C; Simbrunner B; Eigenbauer E; Bauer DJM; Paternostro R; Schwabl P; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T, 2021. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.  Gut 70(9):1758-1767
Costa D; Simbrunner B; Jachs M; Hartl L; Bauer D; Paternostro R; Schwabl P; Scheiner B; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T, 2021. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.  J Hepatol 74(4):819-828
Paternostro R; Traussnigg S; Staufer K; Mandorfer M; Halilbasic E; Lagler H; Stift J; Wrba F; Munda P; Trauner M, 2021. Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease.  Hepatol Res 51(1):69-79
Paternostro R; Pfeiffenberger J; Ferenci P; Stättermayer AF; Stauber RE; Wrba F; Longerich T; Lackner K; Trauner M; Ferlitsch A; Reiberger T; Weiss KH, 2020. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease.  Liver Int 40(4):894-904
Scheiner B; Semmler G; Maurer F; Schwabl P; Bucsics TA; Paternostro R; Bauer D; Simbrunner B; Trauner M; Mandorfer M; Reiberger T, 2020. Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease.  Liver Int 40(1):194-204
Schwarzer R; Reiberger T; Mandorfer M; Kivaranovic D; Hametner S; Hametner S; Paternostro R; Scheiner B; Schneeweiss-Friedl J; Trauner M; Schoefl R; Maieron A, 2020. The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.  J Gastroenterol 55(5):533-542
Paternostro R; Kapzan L; Mandorfer M; Schwarzer R; Benedikt S; Viveiros A; Bauer D; Ferlitsch M; Zoller H; Trauner M; Ferlitsch A, 2020. Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes.  J Gastroenterol Hepatol 35(9):1619-1627
Scheiner B; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Bauer D; Simbrunner B; Schmidt R; Marculescu R; Ferlitsch A; Peck-Radosavljevic M; Pinter M; Trauner M; Reiberger T; Ferenci P; Mandorfer M, 2020. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.  Liver Int 40(2):393-404
Unger LW; Forstner B; Muckenhuber M; Scheuba K; Eigenbauer E; Scheiner B; Pfisterer N; Paternostro R; Trauner M; Mandorfer M; Reiberger T, 2020. Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality.  Dig Dis Sci 65(9):2712-2718
Trieb M; Rainer F; Stadlbauer V; Douschan P; Horvath A; Binder L; Trakaki A; Knuplez E; Scharnagl H; Stojakovic T; Heinemann Á; Mandorfer M; Paternostro R; Reiberger T; Pitarch C; Amorós A; Gerbes A; Caraceni P; Alessandria C; Moreau R; Clària J; Marsche G; Stauber RE, 2020. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure.  J Hepatol 73(1):113-120
Simbrunner B; Marculescu R; Scheiner B; Schwabl P; Bucsics T; Stadlmann A; Bauer DJM; Paternostro R; Eigenbauer E; Pinter M; Stättermayer AF; Trauner M; Mandorfer M; Reiberger T, 2020. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.  Liver Int 40(7):1713-1724
Uschner FE; Glückert K; Paternostro R; Gnad T; Schierwagen R; Mandorfer M; Magdaleno F; Ortiz C; Schwarzkopf K; Kamath PS; Alessandria C; Boesecke C; Pfeifer A; Reiberger T; Kreisel W; Sauerbruch T; Ferlitsch A; Trebicka J; Klein S, 2020. Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction.  Liver Int 40(9):2228-2241
Stift J; Semmler G; Wöran K; Simbrunner B; Scheiner B; Schwabl P; Paternostro R; Pinter M; Stättermayer AF; Meischl T; Beer A; Trauner M; Mandorfer M; Reiberger T, 2020. Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy.  Dig Liver Dis 52(12):1473-1479
Wöran K; Semmler G; Jachs M; Simbrunner B; Bauer DJM; Binter T; Pomej K; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Lampichler K; Pinter M; Trauner M; Mandorfer M; Stift J; Reiberger T; Scheiner B, 2020. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension.  Clin Gastroenterol Hepatol.
Simbrunner B; Semmler G; Stadlmann A; Scheiner B; Schwabl P; Paternostro R; Bucsics T; Bauer D; Eigenbauer E; Pinter M; Stättermayer AF; Quehenberger P; Marculescu R; Trauner M; Mandorfer M; Reiberger T, 2020. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis.  Hepatol Int 14(6):1093-1103
Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M, 2020. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.  United European Gastroenterol J 8(3):321-331
Stift J; Semmler G; Walzel C; Mandorfer M; Schwarzer R; Schwabl P; Paternostro R; Scheiner B; Wöran K; Pinter M; Stättermayer AF; Trauner M; Peck-Radosavljevic M; Ferlitsch A; Reiberger T, 2019. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.  Dig Liver Dis 51(8):1144-1151
Scheiner B; Steininger L; Semmler G; Unger LW; Schwabl P; Bucsics T; Paternostro R; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M, 2019. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.  Liver Int 39(1):127-135
Paternostro R; Heinisch BB; Reiberger T; Mandorfer M; Bardach C; Lampichler K; Seeland B; Schwarzer R; Trauner M; Peck-Radosavljevic M; Ferlitsch A, 2019. Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis.  Hepatol Res 49(2):201-211
Paternostro R; Reiberger T; Bucsics T, 2019. Elastography-based screening for esophageal varices in patients with advanced chronic liver disease.  World J Gastroenterol 25(3):308-329
Semmler G; Simbrunner B; Scheiner B; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Bauer D; Pinter M; Ferenci P; Trauner M; Mandorfer M; Reiberger T, 2019. Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.  J Gastroenterol Hepatol 34(12):2164-2172
Semmler G; Stift J; Scheiner B; Wöran K; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Pinter M; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M, 2019. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.  Dig Dis Sci 64(12):3642-3651
Simbrunner B; Röthenbacher A; Haslacher H; Bauer D; Chromy D; Bucsics T; Schwabl P; Paternostro R; Scheiner B; Trauner M; Mandorfer M; Schwarzinger I; Reiberger T, 2019. Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites.  United European Gastroenterol J 7(5):651-661
Paternostro R; Lampichler K; Bardach C; Asenbaum U; Landler C; Bauer D; Mandorfer M; Schwarzer R; Trauner M; Reiberger T; Ferlitsch A, 2019. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis.  Liver Int 39(12):2374-2385
Semmler G; Scheiner B; Schwabl P; Bucsics T; Paternostro R; Chromy D; Stättermayer AF; Trauner M; Mandorfer M; Ferlitsch A; Reiberger T, 2019. The impact of hepatic steatosis on portal hypertension.  PLoS One 14(11):e0224506
Reiberger T; Bucsics T; Paternostro R; Pfisterer N; Riedl F; Mandorfer M, 2018. Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them?  Curr Hepatol Rep 17(4):301-315
Mandorfer M; Scheiner B; Stättermayer AF; Schwabl P; Paternostro R; Bauer D; Schaefer B; Zoller H; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferenci P; Ferlitsch A, 2018. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension.  Aliment Pharmacol Ther 48(4):451-459
Schwarzer R; Kivaranovic D; Paternostro R; Mandorfer M; Reiberger T; Trauner M; Peck-Radosavljevic M; Ferlitsch A, 2018. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.  Aliment Pharmacol Ther 47(8):1162-1169
Mandorfer M; Schwabl P; Paternostro R; Pomej K; Bauer D; Thaler J; Ay C; Quehenberger P; Fritzer-Szekeres M; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferlitsch A, 2018. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.  Aliment Pharmacol Ther 47(7):980-988
Paternostro R; Heinisch BB; Reiberger T; Mandorfer M; Schwarzer R; Seeland B; Trauner M; Peck-Radosavljevic M; Ferlitsch A, 2018. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.  Liver Int 38(8):1427-1436
Schwarzer R; Kivaranovic D; Mandorfer M; Paternostro R; Wolrab D; Heinisch B; Reiberger T; Ferlitsch M; Gerner C; Trauner M; Peck-Radosavljevic M; Ferlitsch A, 2018. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension.  Aliment Pharmacol Ther 47(1):86-94
Paternostro R; Wagner D; Reiberger T; Mandorfer M; Schwarzer R; Ferlitsch M; Trauner M; Peck-Radosavljevic M; Ferlitsch A, 2017. Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis.  Wien Klin Wochenschr 129(1-2):8-15
Paternostro R; Reiberger T; Mandorfer M; Schwarzer R; Schwabl P; Bota S; Ferlitsch M; Trauner M; Peck-Radosavljevic M; Ferlitsch A, 2017. Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis.  J Gastroenterol Hepatol 32(1):184-190
Rutter K; Etschmaier A; Ferlitsch M; Maieron A; Hametner S; Horvatits T; Paternostro R; Salzl P; Reiberger T; Peck-Radosavljevic M; Quehenberger P; Hofer H; Trauner M; Ferenci P; Ferlitsch A, 2016. von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.  Dig Liver Dis 48(10):1194-9
Bota S; Paternostro R; Etschmaier A; Schwarzer R; Salzl P; Mandorfer M; Kienbacher C; Ferlitsch M; Reiberger T; Trauner M; Peck-Radosavljevic M; Ferlitsch A, 2015. Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine.  Ultrasound Med Biol 41(9):2340-9
Ferlitsch A; Bota S; Paternostro R; Reiberger T; Mandorfer M; Heinisch B; Salzl P; Schwarzer R; Sieghart W; Peck-Radosavljevic M; Ferlitsch M, 2015. Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient.  Liver Int 35(9):2115-20
Publication list retrieved from NCBI using ImpactPubs
.